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Abstract
Background: Prostate cancer is the most common cancer in male in most Western countries, including France.
Despite a significant morbidity and mortality to a lesser extent, the etiology of prostate cancer remains largely
unknown. Indeed, the only well-established risk factors to date are age, ethnicity and a family history of prostate
cancer. We present, here, the rationale and design of the EPIdemiological study of Prostate CAncer (EPICAP), a
population-based case–control study specifically designed to investigate the role of environmental and genetic
factors in prostate cancer. The EPICAP study will particularly focused on the role of circadian disruption, chronic
inflammation, hormonal and metabolic factors in the occurrence of prostate cancer.
Methods/Design: EPICAP is a population-based case–control study conducted in the département of Hérault in
France. Eligible cases are all cases of prostate cancers newly diagnosed in 2012-2013 in men less than 75 years old
and residing in the département of Hérault at the time of diagnosis. Controls are men of the same age as the cases
and living in the département of Hérault, recruited in the general population.
The sample will include a total of 1000 incident cases of prostate cancer and 1000 population-based controls over a
3-year period (2012-2014).
The cases and controls are face-to-face interviewed using a standardized computed assisted questionnaire. The
questions focus primarily on usual socio-demographic characteristics, personal and family medical history, lifestyle,
leisure activities, residential and occupational history. Anthropometric measures and biological samples are also
collected for cases and controls.
Discussion: The EPICAP study aims to answer key questions in prostate cancer etiology: (1) role of circadian
disruption through the study of working hours, chronotype and duration/quality of sleep, (2) role of chronic
inflammation and anti-inflammatory drugs, (3) role of hormonal and metabolic factors through a detailed
questionnaire, (4) role of individual genetic susceptibility of genes involved in biological pathways of interest.
The EPICAP study will also allow us to study prognostic factors and tumor aggressiveness.
Taken together, the EPICAP study will provide a comprehensive framework to go further in the understanding
of prostate cancer occurrence and its prognosis.
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Background
In most Western countries, prostate cancer (PCa) is by
far the most commonly diagnosed cancer in men, which
represents, in France, an estimated 71,220 new cases and
8,685 deaths in 2011 [1]. However, this estimate was
revised down by the French network of cancer registries
FRANCIM, with an estimate closer to 60 000 new cases
per year in France for 2012. A rise in incidence has
been observed in the majority of Western countries,
including France (+8.5% over the period 2000-2005)
partially due to the massive increase in screening by
PSA assay (Prostate-Specific Antigen) since the begin-
ning of the 1990s. Interestingly, this rise in incidence
is also beginning to be observed in countries where
the incidence was very low, especially in Asia [2].
Despite a relatively high morbidity and mortality (3rd
leading cause of cancer death in France), only age, ethnicity
and a family history of prostate cancer are well-established
risk factors of prostate cancer, and except those factors,
the etiology of prostate cancer remains largely unknown
[3,4]. The incidence of prostate cancer varies considerably
with geographical location and ethnic origin with highest
incidence rates observed in Afro-American and French
West Indian populations (> 170 new cases per 100,000)
and lowest incidence rates observed in Asians (< 20 new
cases per 100,000). The majority of Westernised countries,
including France, have incidence rates that vary between
60 and 100 new cases per 100,000.
Interestingly, migrant studies have shown that Asian
men living in the USA have much higher PCa rates than
their counterparts living in native lands, and the inci-
dence of PCa in previously low-risk Asian countries has
increased in parallel to affluence [5]. This suggested the
importance of the environment and lifestyle factors in
prostate cancer etiology and pathogenesis [6,7].
Current research on prostate cancer etiology include
the role of the environment, chronic inflammation, hor-
mones and metabolism, diet and genetic factors with a
growing interest in the complex interrelationships that
may exist between these factors. This is to answer some
of these research questions that we implemented the
EPICAP study, a population-based case–control study,
whose main objective is to investigate the role of environ-
mental and genetic factors in the occurrence of prostate
cancer. A secondary objective will investigate some
prognostic factors and tumor aggressiveness.
The EPICAP study will particularly focused on the role
of circadian disruption, chronic inflammation, hormonal
and metabolic factors and genetic factors in the occur-
rence of prostate cancer.
Circadian disruption and prostate cancer risk
The hypothesis that night work or rotating shift work may
play a role in the occurrence of cancer was raised twenty
years ago trying to explain, at least in part, the increase in
breast cancer incidence in industrialized countries.
Following the publication of several epidemiological
studies, the International Agency for Research on Cancer
(IARC) has classified in 2010 the “shift leading to a disrup-
tion of circadian rhythm” as probably carcinogenic to
humans (Group 2A) on the basis of sufficient evidence
in animals and limited evidence in humans [8].
Disruption of circadian rhythm may increase the risk
of cancer, either by direct disruption of the circadian
clock genes function that control cell proliferation or
due to the disruption of the clock-controlled settings
such as melatonin levels or sleep disorders [9-11]. This
hypothesis was mainly investigated in hormone-related
cancers in women (breast, ovary, endometrium), and
studies regarding the potential effects of circadian dis-
ruption on prostate cancer risk are scarce [12]. Only five
studies have examined the association between night
work and prostate cancer with discordant results [13-16].
A high incidence of prostate cancer has also been
observed among pilots in a meta-analysis [17]. Finally,
one study reported a decreased risk for those sleeping
at least 9 hours per night [18]. This result is consistent
with the fact that nocturnal melatonin secretion is
more important when sleep duration is long and that
melatonin has oncostatic effects of its own.
Chronic inflammation, non steroidal anti-inflammatory
drugs and prostate cancer risk
Chronic inflammation has been associated with the devel-
opment of several cancers via a specific infectious or
environmental agent [19-21]. The presence of inflammatory
infiltrates located near areas of proliferative inflammatory
atrophy (PAI) and prostatic intraepithelial neoplasia (PIN),
considered as precancerous prostate lesions, also helped
to strengthen the hypothesis of a possible link between
chronic inflammation and prostate cancer [22-24]. Several
studies have observed an association with a personal
history of prostatitis or sexually transmitted infection
[25,26]. Sexual activity, as a marker of androgenic activity
due to high sexual activity or a marker of sexually trans-
mitted infection caused by a number of partners, has also
been associated with prostate cancer [27]. In addition,
some studies have reported elevated plasma levels of
pro-inflammatory cytokines or immune response inhibiting
cytokines in men with prostate cancer [28-30]. Finally,
some polymorphisms of genes encoding cytokines have
also been associated with prostate cancer [31-33].
All these elements led to the hypothesis of a possible
reduction in the risk of cancer through the use of non
steroidal anti-inflammatory drugs (NSAIDs) [34-36]. Various
mechanisms have been proposed: induction of apoptosis,
inhibition of angiogenesis, and inhibition of growth by
direct inhibition of cyclooxygenase-2 (COX-2). As in
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mammary tumor cells, overexpression of COX-2 was also
observed in prostate tumor cells [37,38], and higher levels
of prostaglandins have been detected in malignant pros-
tate tissue compared to benign prostate tissue [39]. Several
epidemiological studies report results in favor of a slightly
decreased risk of prostate cancer with aspirin consump-
tion but very few studies have looked at other NSAIDs,
including selective inhibitors of COX-2 [40,41].
Hormones, metabolism and prostate cancer risk
Androgens (testosterone, dihydrotestosterone and their
derivatives) play a central role in the development and
growth of the prostate, however, the precise role of andro-
gens in the development of prostate cancer is far from
clear [42,43]. Indeed, epidemiological studies have shown
conflicting results regarding the role of circulating andro-
gens or other sex hormones in the development of prostate
cancer [44-47]. Interestingly, the role of several markers of
hormonal impregnation such as male premature pattern
baldness, history of acne in childhood or teenage years and
hypofertility/infertility have also been explored in prostate
cancer pathogenesis with contradictory results [48-51].
Clinical, molecular and epidemiological studies have
provided emerging evidence of a possible role of obesity,
involving complex biological pathways such as the
hypothalamic-pituitary-adrenal (HPA) axis, growth fac-
tors, the pancreas and the sympathetic nervous system,
peptide hormones such as leptin and insulin, and more
recently the metabolic syndrome in prostate cancer patho-
genesis [6,52-55]. Although insulin resistance and obesity
are considered at the core of the pathophysiology of
metabolic syndrome, a number of other factors, such as
chronic stress and dysregulation of the hypothalamic-
pituitary-adrenal (HPA) axis, circadian clock system,
proinflammatory state and cellular oxidative stress can
also be involved in its pathogenesis [56]. Therefore,
several mechanisms could explain the association of
obesity and metabolic syndrome with prostate cancer
pathogenesis, including sex steroid hormone, insulin
and insulin-like growth factors and inflammation path-
ways [6,57-59].
Considering the possible link between obesity, metabolic
syndrome and prostate cancer, it has been suggested that
prevention through lifestyle intervention and treatment of
those conditions may reduced the risk of prostate cancer.
Therefore, the possibility of influencing prostate cancer
risk through therapies that alter cholesterol metabolism
such as statins, cholesterol-lowering drugs, has also been
investigated with controversial results [60-62].
Genetic factors and prostate cancer risk
Familial aggregation is now well established with an
increased risk of prostate cancer in patients with a family
history of prostate cancer in first degree relatives [63].
This risk is even more important if the related is a brother
and if the number of affected relatives is large.
Family studies have also shown that some prostate
cancers can be inherited as an autosomal dominant
model and it has been estimated that prostate cancer
family, due to a rare gene with high penetrance, accounted
for approximately 10% of all prostate cancer [64]. Seven
loci have been described, identified and located on sev-
eral genes, especially RNASEL/HPC1, ELAC2/HPC2 and
MSR-1 [64-67].
Some polymorphisms of genes involved in the metab-
olism of steroid hormones (HSD17B, SRD5A2, CYP17,
CYP19, COMT), in the metabolism of xenobiotics (CY
P1A1, CYP1A2, CYP1B1, GSTP1) and in circadian
rhythms (PER1, PER2, CRY1, CRY2, CSNK1E, ARNTL,
CLOCK) have also been associated with the occurrence
of prostate cancer [68-71]. In addition, gene polymorphisms
of circadian rhythms have also been associated with high
concentrations of sex steroid hormones, suggesting a
biological support for the role of genes in the circadian
rhythm of hormone-dependent cancers [72].
Prognostic factors and tumor aggressiveness
PSA is the leader biomarker for early detection, diagnosis,
prognosis and follow-up in prostate cancer. However, at
the time of diagnosis, if high levels of PSA are related
with more aggressive disease, moderate elevation of
PSA cannot distinguish patients with a risk of relapse
to patients with low risk of recurrence and mortality,
those patients deserving active surveillance and not
possibly harmfully treatment. A well-developed prospect-
ive biobank is mandatory for high-quality research of
new tumor markers. Moreover, the recent development
of Liquid Chromatography–Mass Spectrometry (LC-MS)
technology and Reverse Phase Protein Microarray (RPMA),
a high-density quantitative, calibrated, multiplexed array for
protein analysis allows us to develop specific proteomic sig-
natures for PCa prognosis or related to the aggressiveness
of the disease.
Method/Design
We have implemented a population-based case–control
study in the département of Hérault in France. This is
the most suitable type of study for the simultaneous ana-
lysis of several risk factors. A population-based study
achievement through an exhaustive recruitment of the
cases in a well defined geographic area and the recruitment
of the controls in general population offers the advantage
of preventing selection problems as much as possible.
The Département of Hérault was chosen owing to the
existence of a general cancer registry created 26 years ago
(http://www.registre-tumeurs-herault.fr) and of particular
interest for prostate cancers through collaborative projects
with the Regional Association for Clinical Research and
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Consensus in Onco -Urology in Languedoc-Roussillon–
ARCOU (a federation of nearly all urologists, oncologists,
radiotherapists, pathologists, researchers and epidemi-
ologists of Languedoc Roussillon, some of whom are
from the register), because of its agricultural and urban
character, and because of its large size (over one million
inhabitants), which allows the validation of large numbers
of cases (~ 900 validated cases per year) and the collection
of data over a relatively short time period for an epidemio-
logical study. The Hérault department is involved in
the European randomized Study of screening for prostate
cancer (ERSPC) study [73,74].
Cases selection
Eligible cases are all patients newly diagnosed with
prostate cancer in 2012-2013, less than 75 years old
and resident in the department of Hérault at diagnosis.
The case identification is performed by clinical research
nurses recruited and trained specifically for the study in
all participating centers: 3 public hospitals and 3 private
urology clinics. Each clinical research nurses has been
assigned one or more specific health care facilities.
Each clinical research nurses has been assigned one or
more specific health care facilities. The registry allows
us to validate the cases that have been included in the
study. The inclusion of patients in the study was made
only after collecting their consent. Only histologically
confirmed cancer cases were included in the study.
Controls selection
Controls were selected among general population men
free of cancer and resident in the study area (départe-
ment of Hérault) at the time of the cases’ diagnoses. For
including controls, quotas by age were established as a
preliminary to yield the control group similar to the case
group in terms of age in order to achieve frequency-
matching (5 year age group). Quotas by socio-economic
status (SES) were also set a priori to control for potential
selection bias arising from differential participation rates
across SES categories. These quotas by SES were calcu-
lated from the census data available in each study area,
in order to obtain a distribution by SES among controls
identical to the SES distribution among general population
men, conditionally to age. The recruitment of controls
was conducted as follows: phone numbers of private
homes were selected at random via a survey institute
(selected by public procurement) from the telephone
directory of the study area where unlisted numbers had
first been re-created. A phone number was dialed up to
20 times at different times of the day and different days
of the week until contact could be established with the
residents. When a man was living in the residence
reached by phone, he was invited to participate to the
study, as long as the predefined quota corresponding to
his age group and socioeconomic status (SES) was not
completed. When the quota was exceeded, the man
was excluded. The control list of men who accepted to
participate to the study is provided to the research
team on a monthly basis and the controls are contacted
within 2-3 days by clinical research nurses.
Overall, the EPICAP study will include 1000 prostate
cancer incident cases and 1000 population-based con-
trols over a three years period (2012-2014).
Organization
A steering committee, including the coordination team of
the study (principal investigator and study monitor), the
director of the Hérault Cancer Registry (Brigitte Trétarre)
and a referent for urologists (Xavier Rébillard) was set up.
This committee meets every 3-4 months with the three
research clinical nurses in order to maintain nurses’ mo-
tivation and training and to follow the case and control
recruitment as good as possible with the different partners
involved in the study.
The study monitor, Hasina Randrianasolo, is responsible
for the coordination of the 3 clinical research nurses and
for recruitment follow-up, for checking eligibility and
inclusion criteria as well as the receipt of consent, for
the follow-up of interviews of cases and controls, for
the follow-up of samples together with the Biological
Resources Center Epigenetec in Paris and the specialized
biology laboratory of the cancer institute of Montpellier,
for the constant updating of the database for the manage-
ment of the investigation and for drawing up reports on
the state of advancement of the study.
The 3 clinical research nurses have been specifically
trained for this study, particularly in the use of the CAPI
system and with respect to the occupational question-
naires. They are in charge of identifying cases in real
time in collaboration with the physicians and the registry
network, of including cases into the study after obtaining
their consent, of conducting face-to-face interviews with
the cases and controls as well as taking biological sam-
ples from the cases and controls, and of sending the
samples to the Biological Resource Centre in paris and
the specialized biology laboratory in Montpellier. Each
day, the clinical research nurses are in charge of sending
the computerized questionnaire to the survey institute
using an internal network. They are also in charge of
sending the occupational questionnaires to the research
team weekly.
The survey institute (selected by public procurement),
under the supervision of the research team, has been in
charge of the computerization and CAPI formatting of
the study questionnaire, of setting up the database for
the selection of controls by drawing lots through the
geographically random generation of telephone numbers.
It is also in charge of selecting the control group according
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to the study protocol by complying with the recruitment
of monthly quotas and ensuring that consent is obtained,
of providing monthly reports on the quotas and the
recruitment of controls.
The cancer register of the Department of Hérault plays
a central role in the organisation of the study. Indeed,
the study relies on the network of physicians in the
département, set up by the register, who are federated
around the Association for Clinical Research in Onco-
Urology (ARCOU).
The Biological Resource Centre – Epigenetec, located in
Paris, is in charge of the reception, recording (DATABIO-
TEC software), management and storage of biological
samples (EDTA blood samples or Oragen® saliva kits) from
cases and controls.
The specialized biology laboratory in Montpellier is in
charge of the reception, recording, management and
storage of the dry tubes blood samples from cases and
controls. This lab will be responsible for the study of
prognostic factors and tumor aggressiveness under the
supervision of Dr Pierre-Jean Lamy.
Data collection
Cases and controls are face-to-face interviewed by an
experienced research clinical nurse especially trained for
this study and are undergo anthropomorphic measure-
ments. The conditions for data collection are the same for
cases and controls. A blood sample or failing that, a saliva
sample is proposed but refusal does not constitute a
motive for exclusion.
– Questionnaire (Additional file 1)
The interview with cases and controls are carried
out using a system-standardised questionnaire
(CAPI - Computer Assisted Personal Interview), a
face-to-face method for collecting data on a micro-
computer in the home of the interviewee. The inter-
view lasts 2 to 4 hours. The interview allows the
gathering of information concerning the usual socio-
demographic characteristics, a full professional and
residence history, lifestyle and leisure activities, as
well as a personal and family medical history. Ethnic
origin is also carefully recorded.
Data concerning environmental factors include a full
history of the various places of residence, lifestyle
(tobacco and alcohol consumption, Morningness-
Eveningness Questionnaire, duration and quality of
sleep) as well as leisure activities such as gardening,
painting and physical activity.
Data concerning occupational factors include a
detailed occupational questionnaire retracing the full
employment history. For each type of employment
(of more than 6 months), individuals will be asked
for the starting and termination dates, a description
of the job and tasks involved, and the name and
address of the company. Certain professions
(farmers, professional users of pesticides, food or
rubber industry workers, medical workers, night
watchers…) and certain working hours (night work,
rotating shift work) are more specifically
documented using specific occupational
questionnaires. The occupational exposure
assessment will be performed using the
occupational history questionnaire with
job-exposure matrix or a case by case evaluation
by an industrial hygienist expert.
The infectious and inflammatory factors are
recorded by detailed questioning on hospitalizations,
surgery, infectious diseases (uro-genital infections,
sexually transmitted infections…), inflammatory
diseases, medication (non steroidal anti-
inflammatory drugs, antibiotics…).
Data on hormonal and metabolic factors are
collected via questions on the individual’s personal
medical history (diabetes, arterial hypertension,
dyslipidemia, metabolic syndrome…), hormonal
maturation (puberty, acne, Norwood-Hamilton scale of
baldness), medication (anti-diabetic, anti-hypertensive,
cholesterol-lowering drugs, testosterone, etc.),
fertility (conception problems, fatherhood status…),
weight history. A food frequency questionnaire is
also completed.
The family history of cancer in 1st degree and 2nd
degree relatives is examined. For each affected
relative, the localization and age of occurrence of
the cancer is recorded. A full description of 1st and
2nd degree relatives is recorded in order to take into
account the family structure in the analyses.
– Anthropomorphic measurements
The nurses also carried out anthropomorphic
measurements (weight, height and abdominal and
hip perimeter) for both cases and controls. These
measurements complement the data obtained using
the questionnaire.
– Biospecimen collection
Blood sampling is proposed to both cases and
controls and is carried out after signing informed
consent (two dry tubes of 5 ml and two tubes of
7 ml with EDTA as anticoagulant). In case blood
sampling is refused, saliva sampling is proposed
instead, using an Oragene® kit. Blood sampling
allows the constitution of serum and DNA banks.
Cases also gave their consent for the use of their
tumour samples in case of surgery. This allows
the constitution of a tumour bank. Projects which
may be implemented from the tumour bank will
be done in collaboration with all pathologists of
the département.
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– Clinical data
The medical data for all prostate cancer cases are
collected by the clinical research nurses in medical
record of each case in collaboration with the
urologists of each medical department and the
cancer registry of the Département of Hérault.
– Data management
The computerized questionnaires from cases and
controls are monthly returned to the research team
by the survey institute in the form of SAS files. The
data manager is then responsible for checking the files
provided, controlling data quality by setting up logical
checks (answer consistency and outlier search).
Study power
The size of the study will enable detection of minimum
odds ratios of 1.3, 1.4 and 1.7 for exposure whose preva-
lence in controls are 30, 10 and 5 percent, respectively,
with a power of 80 percent, a type-I error of 5 percent
and a number of 1000 cases and 1000 controls.
Based on a literature review and results of previous
studies, prevalence of worthwhile factors is expected to
be mostly more than 5 to 10% in general population for
specific medical conditions or medication of interest and
even being around 35 to 45% for men involved in rotating
shift and night work.
Ethical aspects
Each subject enrolled in the study provides his written
informed consent. In order to protect the confidentiality
of personnel data and to fulfil legal requirements, the
questionnaire included only an identification number,
without any nominative information. The same identifi-
cation number is used for biological samples. The link
between the subject’s name and the identification num-
ber is kept by the research team.
The EPICAP study was approved by the Institutional
Review Board of the French National Institute of Health
and Medical Research (IRB-Inserm n° 01-040 - November
2010) and by the French data Protection Authority
(CNIL N° 910485 - April 2011).
In France, for epidemiological studies that are not
clinical trials, the ethical approval is a global approval
for the study based on the list of participating centers
that are described in the protocol. We also obtained
the approval of all participating centers and approval of
all urologists of these centers.
Pilot study
We conducted a pilot study from June 2011 to January
2012 which allowed us the set up the study in term of:
computerization of the study questionnaire, fluency of
the questionnaire, testing of the questionnaire, setting
up the database for the selection of controls by drawing
lots through the geographically random generation of
telephone numbers, hiring 3 clinical research nurses,
identifying cases in real time in collaboration with the
Hérault cancer registry and physicians, subject’s accept-
ance of the study questionnaire and biological samples.
The pilot study included 61 cases and 121 controls with
a participation rate of 80% for both cases and controls.
All subjects but four (1 case and 3 controls) accepted
the biological sample.
Discussion
EPICAP is large a population-based case–control study
designed to assess the role of environmental and genetic
factors in prostate cancer. EPICAP is drived in département
of Hérault by INSERM Unit 1018 with all urologists and
pathologists involved in the diagnosis and treatment of
prostate cancer cases. This is the most suitable type of
study for the simultaneous analysis of several risk factors. A
population-based study achievement through an exhaustive
recruitment of the cases in a well defined geographic area
and the recruitment of the controls in general population
offers the advantage of preventing selection problems as
much as possible.
Case identification is based on the network of investi-
gators working with the Hérault Cancer Registry and all
health care facilities that support prostate cancer patients
allowing the exhaustiveness of case recruitment of the
study. In order to minimize selection biases, cases were
identified in all cancer hospitals, either public or private,
that recruited prostate cancer patients in the département
of Hérault. Controls are selected from the general popula-
tion in the département of Hérault, using quotas defined
for age and socioeconomic status (SES). The age distribu-
tion of the controls reflects the age distribution of the
cases. In order to avoid selection biais, the SES distribu-
tion of the control group reflects the SES distribution of
the entire département of Hérault to yield the control
group similar to the general population of men of the
same age in terms of SES.
To minimize recall bias that may not completely ruled
out in case–control studies, data were collected by the
same research clinical nurses for cases and controls using
a standardized questionnaire and in the same conditions
of interviewing for both cases and controls. Using the
CAPI (Computed Assisted Personal Interview) system
presents the advantage of not having to spend time on
coding.
The main objective of the EPICAP study is to particu-
larly focus on the role of circadian disruption, hormonal,
metabolic and inflammatory factors in the occurrence of
prostate cancer.
Epidemiological studies that have examined the role
of circadian disruption in the development of cancers
through night work bring up two major problems:
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assessment and quantification of exposure in one hand,
and taking into account other risk factors in the other
hand. Exposure to night work or shiftwork was often
determined on the basis of a simple classification of
subjects “Ever/Never” or based on specific occupational
cohorts. Moreover, the vast majority of the literature
on the role of night work in cancer mainly focuses on
breast cancer and very few studies has been published
on this subject for prostate cancer. The study of the
role of night shift work in prostate cancer is of major
importance in terms of public health due to the increase
in the number of men working at night or with rotating
and staggered schedules in modern societies. Indeed,
35 to 45% of European men had staggered working
hours, including night work, in 2005 [75]. The study of
the role of circadian disruption goes beyond the study
of night work. There is also a need to take into account
the chronotype of the subject as well as the quantity
and quality of sleep.
Given the rising epidemic of obesity and metabolic
syndrome worldwide, especially in developing countries,
and the potential links among obesity, androgen metabol-
ism, metabolic syndrome and inflammation, it is critical to
better understand the complex relations between overall
and abdominal obesity and prostate cancer risk and the
role of chronic inflammation in prostate cancer pathogen-
esis. The act of gathering all these factors of interest in a
given study is essential in order to simultaneously take
into account all these factors.
The identification of polymorphisms that predispose to
prostate cancer and their interaction with “epidemiological”
factors constitutes a major issue in order to better under-
stand the mechanisms of prostate cancer development.
In conclusion, EPICAP is a large population-based
case–control study and the first study of this magnitude
in France mainland. Its main objectives are to investigate
several suspected risk factors whose interest has been
growing worldwide in the last decade. This study was
conceived as part of a comprehensive approach defined
recently as “integrative epidemiology” by Spitz and col-
laborators [76,77]. Indeed, the EPICAP study collects
clinical, biological, epidemiological and genetic data which
will provide a comprehensive framework to go further in
the understanding of prostate cancer occurrence and its
prognostic.
Additional file
Additional file 1: English summarized version of the EPICAP
questionnaire.
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